Bioventus (NYSE:BVS) Updates FY24 Earnings Guidance

Bioventus (NYSE:BVS) updated its FY24 earnings guidance on Tuesday. The company provided EPS guidance of $0.40-0.42 for the period, compared to the consensus EPS estimate of $0.39. The company issued revenue guidance of $562-567 million, compared to the consensus revenue estimate of $561.76 million. Bioventus also updated its FY 2024 guidance to 0.400-0.420 EPS.

Bioventus Trading Down 0.4 %

BVS traded down $0.04 on Thursday, hitting $11.24. 635,211 shares of the company were exchanged, compared to its average volume of 400,782. The company has a debt-to-equity ratio of 1.82, a quick ratio of 0.96 and a current ratio of 1.33. The firm has a fifty day simple moving average of $11.72 and a two-hundred day simple moving average of $8.33. Bioventus has a 12 month low of $3.36 and a 12 month high of $14.38. The stock has a market capitalization of $910.10 million, a PE ratio of 36.08 and a beta of 0.88.

Bioventus (NYSE:BVS) last posted its quarterly earnings data on Tuesday, November 5th. The company reported $0.06 EPS for the quarter, hitting the consensus estimate of $0.06. Bioventus had a positive return on equity of 14.39% and a negative net margin of 7.82%. The company had revenue of $138.96 million during the quarter, compared to analyst estimates of $132.57 million. During the same period in the previous year, the business earned $0.05 EPS. Sell-side analysts expect that Bioventus will post 0.4 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have recently commented on BVS shares. Craig Hallum boosted their price objective on Bioventus from $12.00 to $17.00 and gave the stock a “buy” rating in a report on Friday, September 27th. Canaccord Genuity Group lifted their price objective on Bioventus from $12.00 to $15.00 and gave the stock a “buy” rating in a research report on Wednesday.

Insider Transactions at Bioventus

In other news, Director John A. Bartholdson acquired 25,500 shares of Bioventus stock in a transaction that occurred on Monday, August 19th. The stock was purchased at an average cost of $8.55 per share, with a total value of $218,025.00. Following the completion of the acquisition, the director now owns 6,939,357 shares in the company, valued at $59,331,502.35. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, Director John A. Bartholdson acquired 80,000 shares of Bioventus stock in a transaction on Friday, August 16th. The stock was purchased at an average price of $8.55 per share, with a total value of $684,000.00. Following the completion of the purchase, the director now owns 6,913,857 shares of the company’s stock, valued at approximately $59,113,477.35. The trade was a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director John A. Bartholdson acquired 25,500 shares of the business’s stock in a transaction dated Monday, August 19th. The stock was purchased at an average price of $8.55 per share, with a total value of $218,025.00. Following the completion of the acquisition, the director now directly owns 6,939,357 shares in the company, valued at approximately $59,331,502.35. This represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. Insiders own 32.90% of the company’s stock.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.